2014 EuropaBio EY Report on Biotechnology in Europe
The Tax, Finance and Regulatory Framework and Global Policy Comparison.
European governments must remain committed to biotech research, development and innovation (RDI) incentives as the industry faces fresh challenges of upholding its world leading position of innovation, maintains the biennial report published today by EY and EuropaBio: ‘Biotechnology in Europe: The Tax, Finance and Regulatory Framework and Global Policy Comparison’.
The report provides a comprehensive study of the leading 17 European biotech countries comparing their advantages and disadvantages. The survey analyses the tax, financial and regulatory incentives these individual jurisdictions provide to investors, entrepreneurs, manufacturers and researchers. It also weighs the financial burdens for SMEs and which benefits are likely to flow from a decision to establish a research facility or start-up in a particular market. Key non-EU global locations for biotechnology were also profiled on the increasingly important topic of R&D incentives. The report surveyed 9 comparable markets across North America, Australasia and emerging regions. The global comparison highlights the increasingly important topic of R&D incentives. Additionally, the report contains detailed discussions with top industry and venture capital stakeholders about their visions for the future of the industry in Europe.